Heron Therapeutics, Inc 10-Q for FY2026 Q3
Heron Therapeutics, Inc. (HRTX)
10-Q
2026-11-09
For: 2026-09-30
View Original
Added on
November 09, 2026
About this 10-Q
Heron Therapeutics, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $35.25M
- down 7.8% from $38.21M a year earlier
- Net loss
- $5.01M
- compared with a net loss of $17.5M a year earlier
- Diluted EPS
- -$0.03
- compared with -$0.10 a year earlier